**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 55090

**Manuscript Type:** REVIEW

**Gut microbiota and diabetes: From correlation to causality and mechanism**

Li WZ *et al*. Gut microbiota and diabetes

Wei-Zheng Li, Kyle Stirling, Jun-Jie Yang, Lei Zhang

**Wei-Zheng Li, Lei Zhang,** Microbiome-X, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Key Laboratory of Big Data-Based Precision Medicine, Beihang University, Beijing 100191, China

**Wei-Zheng Li,** School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China

**Kyle Stirling,** Luddy School of Informatics, Computing and Engineering, Indiana University, Bloomington, IN 47408, United States

**Kyle Stirling,** The Crisis Technologies Innovation Lab, Indiana University, The Information Technology Services and the Pervasive Technology Institute, Bloomington, IN 47408, United States

**Kyle Stirling, Lei Zhang,** Shandong Institute of Industrial Technology for Health Sciences and Precision Medicine, Jinan 250000, Shandong Province, China

**Jun-Jie Yang,** College of Life Science, Qilu Normal University, Jinan 250000, Shandong Province, China

**Jun-Jie Yang,** Microbiome Research Center, Shandong Institutes for Food and Drug Control, Jinan 250000, Shandong Province, China

**Jun-Jie Yang,** Shandong Children’s Microbiome Center, Qilu Children's Hospital of Shandong University, Jinan 250000, Shandong Province, China

**Jun-Jie Yang,** Microbiological Laboratory, Lin Yi People’s Hospital, Linyi 276000, Shandong Province, China

**Jun-Jie Yang,** Qingdao Human Microbiome Center, The Affiliated Central Hospital of Qingdao University, Qingdao 266000, Shandong Province, China

**Lei Zhang,** Institute for Medical Dataology, Cheeloo College of Medicine, Shandong University, Jinan 250000, Shandong Province, China

**Lei Zhang,** Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250000, Shandong Province, China

**Lei Zhang,** Shandong Children’s Microbiome Center, Research Institute of Pediatrics, Qilu Children's Hospital, Cheeloo College of Medicine, Shandong University, and Jinan Children's Hospital, Jinan 250022, Shandong Province, China

**Author contributions:** Zhang L designed the framework and supervised the preparation; Li WZ collected all references, wrote the manuscript, prepared the figure and table; Stirling K, Yang JJ and Zhang L contributed to thorough revision of the manuscript; All authors have read and approve the final manuscript.

**Supported by** Shandong Provincial Key Research and Development Program, No. 2018CXGC1219; City of Weihai Technique Extension Project, No. 2016GNS023; TaiShan Scholars Program of Shandong Province, No. tshw20120206; and TaiShan Industrial Experts Program, No. tscy20190612.

**Corresponding author:** **Lei Zhang, PhD, Chairman, Professor,** Microbiome-X, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Key Laboratory of Big Data-Based Precision Medicine, Beihang University, 37 Xueyuan Road, Haidian District, Beijing 100191, China. [microbiome@foxmail.com](mailto:microbiome@foxmail.com)

**Received:** February 29, 2020

**Revised:** May 21, 2020

**Accepted:** June 10, 2020

**Published online:** July 15, 2020

**Abstract**

In this review, we summarize the recent microbiome studies related to diabetes disease and discuss the key findings that show the early emerging potential causal roles for diabetes. On a global scale, diabetes causes a significant negative impact to the health status of human populations. This review covers type 1 diabetes and type 2 diabetes. We examine promising studies which lead to a better understanding of the potential mechanism of microbiota in diabetes diseases. It appears that the human oral and gut microbiota are deeply interdigitated with diabetes. It is that simple. Recent studies of the human microbiome are capturing the attention of scientists and healthcare practitioners worldwide by focusing on the interplay of gut microbiome and diabetes. These studies focus on the role and the potential impact of intestinal microflora in diabetes. We paint a clear picture of how strongly microbes are linked and associated, both positively and negatively, with the fundamental and essential parts of diabetes in humans. The microflora seems to have an endless capacity to impact and transform diabetes. We conclude that there is clear and growing evidence of a close relationship between the microbiota and diabetes and this is worthy of future investments and research efforts.

**Key words:** Diabetes; Microbiota; Causality; Mechanism; Type 1 diabetes; Type 2 diabetes; Insulin resistance; Inflammation; Metabolites

**Citation:** Li WZ, Stirling K, Yang JJ, Zhang L. Gut microbiota and diabetes: From correlation to causality and mechanism. *World J Diabetes* 2020; 11(7): 293-308

**URL:** https://www.wjgnet.com/1948-9358/full/v11/i7/293.htm

**DOI:** <https://dx.doi.org/10.4239/wjd.v11.i7.293>

**Core tip:** Current research continues to uncover associations between microbiota and diabetes [type 1 diabetes (T1D) and type 2 diabetes (T2D)], and these appear to involve metabolic effects and immune response processes. Understanding the consequences of balance in human gut microbiota and diabetes may prove very useful in developing future therapeutic interventions. This review summarizes recent studies in both mouse models and human cases that support a potential cause-effect relationship, and discusses the role of gut microbial metabolites on T1D and T2D.

# INTRODUCTION

Recently, studies of the human microbiome are capturing the attention of scientists and healthcare practitioners worldwide by focusing on the interplay of gut microbiome and diabetes. Understanding the consequences of balance in human gut microbiota and diabetes should prove very useful in developing future promising therapeutic interventions. Diabetes is a common chronic endocrine and metabolic disease, which impacts humans globally. Type 1 diabetes (T1D) is prevalent among children and adolescents, although the disease can occur at any age. The pathogenesis of T1D occurs when the endocrine system cannot produce insulin due to an autoimmune-mediated response leading to both inflammation and destruction of pancreatic β-islet cells. Type 2 diabetes (T2D) is a more prevalent form of diabetes most commonly occurring among adults and is usually caused by a combination of insulin resistance and an insulin deficiency.

Among the risk factors associated with diabetes are often things like a family history of diabetes, unhealthy eating habits, and obesity. The increasing prevalence of diabetes is a worldwide phenomenon following the continuous growth in urbanization, changes in diet, and the emergence of more sedentary lifestyles. According to a 2019 report, about 463 million adults worldwide currently have diabetes and future projections indicate the number of diabetic patients will reach 700 million by 2045[1]. According to epidemiological observations, specific changes in the diversity of intestinal microflora are one of the characteristics of diabetic patients[2]. At the same time, there is also growing evidence of a close association between gut microbiota and diabetes[3].

The human gut is a complex ecosystem consisting of microbiome, host cells and nutrients[4]. There are about 100 trillion bacteria in the intestinal tract and they form the gut microbiota. Gut microbiota are composed of many diverse species of bacteria. These are taxonomically classified by genus, family, order and phylum. The intestinal microflora of healthy adults principally consists of six phyla: Firmicutes, Proteobacteria, Bacteroidetes, Actinobacteria, Fusobacteria and Verrucomicrobia. *Bacteroides* and Firmicutes occupy the dominant position in the human intestinal tract and play a pivotal role in the nutritional absorption system and support intestinal barrier enhancement. Genomic analysis of lean mice and healthy humans also confirmed the dominance of Firmicutes and Bacteroidetes, and most research indicates that *Bacteroides* outnumber Firmicutes[5].

Current research continues to find associations between microbiota and diabetes (T1D and T2D), and these appear to involve many metabolic effects and immune response processes, and most of these associate with more specific mechanisms. Some of the future research activities exploring gut microbiota balance variations and diabetes will lead to new interventional experiments, and potential evaluation of a causal hypothesis. This review provides an overview of studies that focuses on gut microbiota balance in humans with diabetes. So far, we know there is a range of recent evidence leading to some support for the potential causal role of gut microbiota in aspects of diabetic disease. It is now clear that future research will examine the potential for and discovery of the microbiota-related underlying mechanisms of diabetes[5,6]. It is only a matter of time and effort to follow the increasing evidence supporting these linkages.

# DIET IS A CRUCIAL REGULATOR OF INTESTINAL MICROFLORA

The composition of the microbial community ecosystem is dynamic and its composition is dependent upon many factors[7]. Recent experiments using animal models indicate that intestinal microflora is regulated by factors including genes, medication, and diet. The gut microflora is easily altered by dietary changes. Experiments have shown that dietary changes can induce temporary shifts in a large number of microorganisms as rapidly as within 24 h[8]. Since diet is the main source of energy for individuals and a crucial method for humans to maintain health and growth, the diet composition has a big impact on gut microbiota[9]. It therefore follows that diet is also a vital regulator of gut microbiota. Gut microbiota composition also varies with an individual’s age, and studies have shown these age-related gut microflora changes could possibly occur due to changes in diet at different ages and changes in inflammation due to some age-related diseases and changes leading to decreased immune system function[10]. At the same time, the varying composition of gut microorganisms has been identified in disparate geographical regions and this may also be related to different regional eating habits[11]. The gut microflora plays a pivotal role in the body's metabolism and immunity responses can also become a regulator of the effect of diet on the host's metabolic state[12]. On the other hand, these factors may also provide a potential impact on the onset of metabolic diseases like diabetes. The type, quality, components and source of human food intake will affect the composition of gut microbiome, as well as the functions and interactions in the microbiome ecosystem.

The main energy source of the gut microflora is dietary carbohydrates. The incidence of T2D is inversely associated with the total amount of dietary fiber intake. Dietary fiber is also found to impact intestinal microflora populations, and research indicates that fiber intake is associated with an increase in microbial diversity and the ratio of Firmicutes/Bacteroidetes[13]. Some studies have confirmed that an increase in dietary fiber intake also increases the abundance of the human intestinal microflora and leads to higher microflora richness. Fiber intake is also associated with higher microflora stability[14]. Dietary fiber intake promotes the fermentation of intestinal microbes and this appears to cause an increase in short-chain fatty acids (SCFAs) metabolites. As ligands of free fatty acid receptor 2 (FFAR2) and free fatty acid receptor 3 (FFAR3), SCFAs participate in the regulation mechanism of glucose homeostasis[15]. Propionic acid is reported to be produced mainly by threonine[16]; glycine, glutamic acid, lysine, ornithine and aspartic acid can be used to synthesize acetate; threonine, glutamic acid and lysine acid can be used to synthesize butyric acid, of which threonine can produce three main SCFAs[17]. Studies have reported that soluble fiber has a direct blood glucose lowering effect. Intake of soluble dietary fiber increases the viscosity of gastric juices, the more viscous fiber leads to gastric emptying times that are longer. Additionally these changes lead to small intestine transit time slowing, and increased starch digestion, which is associated with a reduced rate of glucose absorption, leading to changes in blood glucose and cholesterol concentrations[18]. Consuming more dietary fiber appears to reduce the risk of T2D, and is also associated with maintaining a healthy weight. Healthy adults and children can increase their intake of plant foods rich in fiber, while reducing total energy intake that is more often associated with high-sugar, high-fat, and low-fiber foods[19]. Nevertheless, some SCFAs appear to be involved in some of the mechanisms associated with diabetes, which also establishes the link between microbiota and diabetes[17,20].

A recent study combined measurements of intestinal microbiome diversity with diet history, and blood test parameters from volunteers. These data were evaluated using machine learning algorithms to predict how an individual’s postprandial blood glucose production responded to real-life diets[21]. This study indicated that a personalized diet can successfully improve postprandial blood glucose elevation[21]. By combining these techniques and big data analysis, and the use of more specific medicinal nutrition recommendations shows the possible prevention and management of T2D with more effective personalized nutrition guidance. The widespread use of personalized nutrition also faces many challenges, such as the historic lack of reliable and repeatable results, also there are omics technology problems such as high cost, and the need for more research evidence to support actual effectiveness[22].

In addition to SCFAs, intestinal microflora appears to regulate lipopolysaccharide (LPS) levels and these levels are also thought to be involved in the development of diabetes[23]. Patients with T2D have fewer butyrate-producing bacteria than non-diabetic patients. Additionally, the ratio of Firmicutes/Bacteroidetes is also significantly lower in T2D patients than in non-diabetic patients[24]. By reviewing the results from across numerous studies, we can observe which intestinal microflora types and balances are co-occurring and possibly correlated with diabetes. In T2D patients, there is an abundance of *Bacteroides*, *Faecalibacterium*, *Akkermansia*, and there are lower concentrations of *Roseburia*, while *Ruminococcus* and *Fusobacterium* are elevated. Gut microbiota was also reported to have a relationship with T1D in previous studies[25]. Gut microbial communities appear to have an impact starting in infancy, and it is speculated that T1D is possibly related to the early effects of the gut microbiome. The interaction between the human body and the intestinal microflora appears to start at birth, and the development of the gut microbiome then evolves and goes through three fundamental stages: the first is a developmental stage (occurring during months 3-14), the second is a transition stage (occurring during months 15-30) and finally the third stage is a stable period (occurring during months 31-46)[26]. Abnormal gut microbiota is often observed in pre-diabetic patients. A controlled study was conducted to analyze 134 Danish patients with prediabetes. When these subjects were compared with normal controls, the intestinal microflora of patients with prediabetes showed abnormal characteristics, with low concentrations of *Clostridium* and mucin-degrading *Akkermansia muciniphila*[27]. In another study, vertical stool samples from 903 children aged 3-46 mo were analyzed, and the study found that early intestinal microorganism ecology is impacted by breastfeeding and childbirth[26]. The full implications of these observations, although not conclusive, appear to indicate that there is a developmental impact on microbiome development and the strength and outcome of these factors will need to be more fully explored in future research.

# STUDIES USING ANIMAL MODELS

The mouse model is commonly used in the study of intestinal microflora, and the function of the intestinal microflora can model that for mammals. Studies using mice as models provide important insights and help to build an understanding of the relationship between the intestinal microflora and diabetes. Mice are generally used as the preferred model for research, because the intestinal structures of mice and human subjects are quite similar. These models can also provide an evaluation of experiments designed to disturb the intestinal microbiota using controlled experimental apparatus. Closer observations of the microbiota composition is helpful in identifying and evaluating the potential causal relationships and possible mechanism of the interaction between host and intestinal microorganisms[28]. Although there is more work to be accomplished here, it is expected that a better understanding of how these balances in microbiota impact both health and diabetic disease processes will be forthcoming.

It is important to note that previous research indicated that when mice do not have gut microbiota (germ-free mice) they also have lower body fat and insulin resistance than conventional mice, and the tolerance of insulin and glucose in germ-free mice was higher than that observed in routinely fed mice. This study also paved the way for the examination of many potential mechanisms in the past decade[29]. This was followed by a subsequent intestinal microflora transplantation experiment, and the germ-free mice that received transplanted gut microflora from ob/ob mice showed a significant increase in obesity with associated insulin resistance[30]. In subsequent weight-loss surgery experiments, the correlation between obesity and intestinal microflora was also demonstrated, with an observed increase in fat mass in germ-free mice transplanted with altered microbiome[31].

In a recent study, the Koch hypothesis was a useful method to examine the possible causal link between gut microflora and obesity[32]. These studies all started to substantiate the potential cause-and-effect relationship. However, the results of gut microbiological studies in mouse models cannot be simply directly translated into human comparisons and these pitfalls of direct comparisons need to be avoided until more evidence from human studies can be completed to evaluate any potential causality.

# TRANSLATIONAL STUDIES AND EXPLORATIONS

Studies in mouse models support the hypothesis of potential causality between gut microbiota and the development of obesity and diabetes, but so far there has been little research completed related to causality in human subjects. The reproducibility of human experimental studies is also sometimes limited, which may also be influenced by variations in differences among study settings, geographic locations of sample preparation, as well as inconsistencies in data analysis. Moreover, there are some studies which have produced contradictory observations and data in human research. It is unclear, as to the root cause of this variation; however, it may be partially attributed to different dietary habits and environmental/cultural factors around the world as well as to different experimental methods used. However, future conclusions regarding human microflora connections to diabetes will require intervention studies to determine if there is a causal relationship with microflora as a driving factor for disease development. To date, fecal microbiota transplantation (FMT), antibiotic therapy, diet, and probiotic therapy are considered effective in various intervention studies[33].

Contemporary research shows that FMT has also been considered an effective tool to gain evidence of microbiome association and the causality of many diseases[34]. In a randomized, double-blind controlled experiment of insulin-resistant men, patients received gut microbiota from lean body mass donors, and analysis of the experimental results demonstrated that FMT improved insulin sensitivity and the number of butyrate-producing bacteria also increased significantly. However, not all patients receiving FMT from lean donors experienced the same beneficial effects, and more research is required for comparative analysis[35].

Metformin

Forslund *et al*[36] proposed that changes in gut microbiome in diabetic patients are not entirely endogenous and can be explained in a large part by metformin treatment. Upregulation of glucagon-like peptide-1 (GLP-1) and peroxisome proliferator-activated receptors has been reported in healthy individuals and in T2D patients after metformin treatment. Metformin is also an insulin hormone regulator that has multiple effects in the intestine, such as increasing GLP-1 concentration in the intestine and extraction of glucose[37]. Metformin can reduce lipid absorption and inflammation caused by LPS, and can also reverse T2D-related changes because the abundance of several gut microbiota appears more similar to non-diabetic control levels when treated with metformin[36].

Recent studies have shown that metformin disrupts the microbial characteristics associated with diabetes, including changes in the composition of the intestinal microflora[38]. A double-blind, placebo-controlled experiment of T2D patients showed that metformin altered the intestinal microflora balance in treatment-naive T2D patients, while germ-free mice had glucose tolerance after receiving metformin-modified microbiota and showed improved results[39]. Metformin was used in a controlled experiment in mice fed a high-fat diet (HFD), and the results showed that the abundance of the mucin-degrading bacteria *Akkermansia muciniphila* (*A. muciniphila*) was higher than that observed in the control group[40]. Similar conclusions have been found in other human studies[41]. A recent study analyzed the gut microbiome of Chinese T2D patients receiving different anti-diabetes drugs, and metformin recipients showed enrichment of *Turicibacter* and *Spirochaete*[42]. Another study used genomic analysis to analyze the composition of intestinal microflora in diabetic patients taking metformin. The results showed that *A. muciniphila* and several SCFAs-producing microbiota were low when compared to non-diabetic patients who had a relatively high abundance, and this study revealed some of the mechanism by which metformin changes the composition of intestinal microflora by enriching *A. muciniphila* and several SCFAs-producing microbiota[41].

Probiotics and intervention experiments

Probiotics appear to have a wide range of effects on the host, including improved regulation of insulin sensitivity, which may also be related to host metabolism mediated by the gut microbiome balance, by improving host metabolism composition, by reducing pro-inflammatory cytokines, and by reducing intestinal permeability[43]. In addition, probiotics have the potential to directly improve host metabolism and increase SCFAs production. Supplementing probiotics can also improve intestinal balance through the production of antibacterial compounds and competition with pathogens. Probiotics may also regulate the host's immune response, and activate specific gene activation and impact extra-intestine processes and disorders[44].

Numerous experiments in mouse models and human experiments have confirmed that multiple probiotics reduce insulin resistance by affecting gut microbiota and consequently, may influence health. Preliminary studies have shown that ingestion of fermented dairy products such as yogurt can transport lactic acid bacteria to the gut, alter gut microbial composition, inhibit the production of LPS, and increase the close connection of gut epithelial cells[45]. At the same time, a prospective, double-blind, randomized trial of 21 people with high glucose tolerance showed that oral administration of *Lactobacillus reuteri* also improved insulin secretion[46].

Recently, *A. muciniphila* has been frequently mentioned in current studies, and these studies show it reduces insulin resistance and reduces destruction of the intestinal barrier. *A. muciniphila* was reported to be less abundant in pre-diabetic patients, as well as among newly diagnosed T2D patients, suggesting that the low levels of *A. muciniphila* may be a biomarker for impaired glucose tolerance[47]. A recent study found that *A. muciniphila*-derived extracellular vesicles (AmEVs) can regulate gut permeability. The analysis of fecal samples revealed that AmEVs levels were low in T2D patients. Moreover, in a study of diabetic mice, the administration of AmEVs was associated with an observed decrease in fat content and an increase in glucose tolerance in diabetic mice[48]. Studies in mouse models have shown that supplementation with *A. muciniphila* can reduce low-grade inflammatory responses and metabolic disorders[49]. In another study of HFD mice, *Akkermansia* was reported to be associated with reduced LPS levels, which may be related to the ability of *Akkermansia* to maintain mucus layer thickness, which reduces intestinal permeability and LPS leakage[50]. *A. muciniphila* is a mucus-degrading bacterium, and its abundance is negatively correlated with glucose tolerance and fat accumulation in mouse models, but more evidence needs to be acquired in human studies to establish clear results[51]. The mechanism of decreasing insulin sensitivity of *A. muciniphila* may also be related to its membrane protein. Amuc\_1100 is a special membrane protein isolated from *A. muciniphila*. Studies have shown that the special protein binds to Toll-like receptor 2 (TLR2) and participates in the protective mechanism of the intestinal barrier[52].

Clinical experiments are increasing in frequency and new results are encouraging. A recent randomized, double-blind placebo trial of 40 insulin-resistant adults who were orally supplemented with *A. muciniphila* showed that it played a role in reducing biomarkers associated with inflammatory responses, these biomarkers have also been linked to diabetes. Experiments have also shown that *A. muciniphila* improves insulin sensitivity in patients[53].

However, the regulatory effects of probiotics on improving insulin sensitivity have population limitations and may not work for everyone. It is worth noting, for example, that two recent studies have shown that probiotics have no effect on gestational diabetes as this disorder appears entirely hormonal[54,55].

# METABOLIC PRODUCTS AFFECT THE UNDERLYING MECHANISMS

Obesity and T2D are often characterized by changes in intestinal microflora, inflammation, and disruption of the intestinal barrier. Chronic, low-grade inflammatory response is a common characteristic of T2D and obesity, and this systemic inflammatory response is also thought to drive insulin resistance. Previous research in mouse models has confirmed that the intestinal microflora is responsible for the increased inflammatory response in obese patients[28]. Furthermore, the gut microbiome can interact with dietary components and habits to influence host insulin sensitivity, intestinal permeability, glucose and fat metabolism[56]. The gut microbiota has long been regarded as a virtual organ of human metabolic activity[57], and its metabolic activity interacts with insulin resistance and diabetes. Gut microbial metabolites can affect host physiological functions. Metagenomic analysis showed that the intestinal microflora of T2D patients and healthy individuals is often markedly different, and the decline in butyrate-producing bacteria may be the cause of impaired glucose metabolism[58]. Modification of gut microbiota caused by external interventions such as diet leads to dysregulation and secretory changes of intestinal microbial metabolites, triggering a variety of potential mechanisms leading to insulin resistance and diabetes. At the same time, intestinal microflora can also affect metabolism and the potential risk of diabetes by changing the way they respond to dietary ingredients[12]. There are many ways to interact with the host and intestinal microorganisms, and in the past decade, many studies were conducted to understand mechanisms for the analysis and hypothesis of microflora involved in regulating insulin resistance, including LPS and SCFAs. Most of the studies have focused on triggering the markers of diabetes: a low-grade inflammatory response and an immune response, in which intestinal microflora and its metabolites play a key role[5].

LPS

LPS is reported to induce inflammatory cytokines through immune cells and adipocytes, causing low-grade inflammation, while acetic acid or butyrate can regulate the function of immune cells. According to Gram staining analysis, the two most common phyla in clinical classification belong to different groups, namely Gram-positive bacteria and Gram-negative bacteria. LPS is derived from the cell wall of Gram-negative bacteria[59]. The LPS of gut microbiota binds to Toll-like receptor 4 (TLR4), then it initiates a signal cascade with good characteristics, inducing the inflammatory response and the expression and secretion of cytokines[60]. The TLR4 signaling pathway is considered to be one of the main triggers of the obesity-induced inflammatory response. Studies have shown that saturated fatty acids can cause insulin resistance and low-grade inflammation by activating the TLR4 signaling pathway[61]. At the same time, different studies have shown that TLR2 is also involved in the inflammatory response when the signaling cascade caused by LPS-LBP-TLR4 is activated[15]. The integrity of the gut barrier seems to play a crucial role in the development of obesity and T2D. The intestinal epithelium acts as a barrier, and its basic function is to limit the interaction between the intestinal microflora, the basic local immunity and other parts of the body[62]. The integrity of the gut barrier can maintain the functional balance of the mucosa, which can be maximally absorbed while maintaining an effective defense response[63]. Increased production of LPS by the intestinal microflora will also activate the endocannabinoid system. In addition, too much LPS may destroy the integrity of the intestinal barrier, and increase LPS absorption[64]. Animal studies have indicated that LPS is involved in the regulation of diabetes-related mechanisms, which can be characterized by the occurrence of increased inflammatory response[65].

SCFAs

SCFAs are composed of acetic acid, propionic acid and butyric acid. The deficiency in SCFAs is thought to be associated with T2D. Currently, studies have shown there is confirmation that SCFAs have a protective effect on the gut barrier, and result in a decrease in the number of butyrate-producing bacteria that may lead to changes in intestinal permeability. Studies have shown that butyrate can promote the expression of tight junction proteins and affect the mucosal barrier function[66], while acetate has also been reported to have a good performance in reducing mucosal permeability and enhancing the intestinal barrier function[67]. The SCFAs mechanism involves activation of G proteins of the L-cells to promote the release of GLP-1 and peptide YY (PYY) to regulate glucose homeostasis, and at the same time, the SCFAs also effect the intestinal barrier, up-regulate 5'-AMP activated in muscle and liver tissues and the protein kinase signaling pathway, which are related to insulin resistance and inflammation, and oxidative stress may have a potential role[43].

Clinical studies have shown that dietary fiber promotes SCFAs production by gut microorganisms, while most other potential producers are relatively reduced in T2D patients[68]. In a recent study, intestinal microflora before and after dietary fiber interventions in volunteers were transplanted into germ-free mice. The study indicated the strong and significant association between gut microbiome and improved fiber glucose-induced host glycemic control. At the same time, the study proposed that when the SCFAs-producing bacteria promoted by dietary fiber have greater abundance and diversity, participants' glycated hemoglobin levels were improved[68]. On the other hand, SCFAs activate the vagal afferent neurons, which establish a connection between the intestinal information and the brain. This connection has been proved to play a role in controlling human feeding behavior, which also raises new considerations for the potential mechanism of SCFAs in increasing the risk of diabetes by controlling human feeding behavior and selection of dietary response[69].

In a recent study, genome-wide genotyping, intestinal genomic sequences, and fecal SCFAs level information from 952 normal blood glucose individuals were synthesized. A two-way Mendelian randomization (MR) analysis was used to assess causality, and the results showed that butyrate and propionate were proved to be involved in a causal relationship with diabetes, with oral glucose tolerance test showing a positive correlation between butyrate and improved insulin resistance and between malabsorption of propionic acid and the incidence of T2D, which offers evidence for the causal effect of gut microbiota on metabolic characteristics[70].

Butyrate

In a fecal bacteria transplantation experiment, insulin resistance patients received fecal microflora from insulin-sensitive donors, which resulted in a significant improvement in insulin sensitivity with increased abundance of butyrate-producing bacteria[71]. Through the analysis of human fecal samples, *Faecalibacterium prausnitzii* (*F. prausnitzii*) was found to be the main butyrate-producing bacteria. The abundance of *F. prausnitzii* and *Roseburia* in intestinal microflora of T2D patients is lower than that of healthy individuals, according to large scale metagenomic association studies in different populations[72]. Other studies have also demonstrated that the enrichment of *F. prausnitzii* can reduce inflammatory symptoms and insulin resistance. *Roseburia spp.* is also a butyrate-producing bacteria, which has a pivotal part in maintaining intestinal health and immune defense. It can regulate the dynamic balance of T cells by producing butyric acid[73]. Butyrate has a protective effect on the intestinal barrier by inducing the synthesis of mucin, it reduces the intestinal permeability and prevents bacteria from passing through. Butyrate also acts on the colonic epithelium, reducing oxidative stress and inflammation. In addition, the abundance of butyrate-producing bacteria is lower in prediabetic patients than in healthy people[27], which may indicate that the absence of butyrate-producing bacteria is one of the precursors of diabetes.

Bile acids and branched-chain amino acids

Bile acids are synthesized in the liver, and are transformed into secondary bile acids through the enzyme metabolism of gut microbiota[74]. In an experiment on rats, the intestinal microflora of oral bile acid treated rats was analyzed and showed there were significant changes in phylum levels and an increased ratio of Firmicutes/Bacteroidetes[75]. Secondary bile acids are associated with the regulation of insulin sensitivity through activation of Farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor 5 (TGR5) receptors[76]. A study reported reduced genetic and diet-induced insulin resistance in FXR knockout mice[77]. FXR activation induces increased secretion of fibroblast growth factor 19 (FGF19 in humans, FGF15 in rodents), which improves glucose tolerance and insulin resistance[78]. Activation of the TGR receptor stimulates intestinal L cells to secrete GLP-1, thereby improving insulin sensitivity[79].

Branched-chain amino acids (BCAA) are thought to be related to the risk of developing T2D and are considered to be predictive markers for T2D[80,81]. Several studies have reported decreasing plasma BCAA levels in T2D patients[82,83].

A large cohort study also demonstrated the strong association between BCAA and diabetes, as well as the potential role of amino acid metabolism in the early stage of diabetes[80]. Studies in rats have demonstrated that high-fat dietary supplementation with BCAA also leads to insulin resistance[84]. Human studies have confirmed the conclusion that supplementing BCAA in diet increases the risk of T2D and insulin resistance[85]. In a recent study, patients with T2D received a short-term dietary supplement of BCAA, which showed reduced insulin secretion after a meal and changes in the composition of the intestinal microflora. The synthesis pathway of BCAA has been shown to be related to *Prevotella copri* (*P. copri*) and *Bacteroides vulgatus* in intestinal microflora[86]. Subsequent experiments showed increased BCAA levels and increased insulin resistance in germ-free mice transplanted with *P. copri*[86]. The mechanism of BCAA inducing insulin resistance has been proposed to be attributed to the increased oxidation of free fatty acids and the activation of phosphatidylinositol 3-kinase (PI3K)[87]. However, the exact mechanism is still unclear and needs further study.

# GUT MICROBIOTA AND T1D

Both T1D and T2D are associated with complex immune system and gut microbiome interactions. Gut microbiota disorders are associated with the pathogenesis of T1D, and the incidence of T1D is related to the interaction of gut microbiota and the innate immunity. Non-obese diabetic (NOD) mice have developed into the prototype model of T1D. The occurrence of T1D in NOD mice depends on the composition of gut microflora and LPS-mediated gut signals involving TLR4 and MyD88[88]. MyD88 is a key signal transduction factor in interleukin (IL)-1 and TLR signal transduction pathway. Its defect alters the composition of distal intestinal microflora. Studies have reported that NOD mice lacking MyD88 protein will not develop T1D[89]. In the follow-up study, the gut microflora of MyD88-deficient NOD mice protected by diabetes was transferred to wild-type NOD female mice, which reduced the intensity of pancreatitis and significantly delayed the occurrence of autoimmune glycosuria[90].

The gut microflora of preclinical T1D patients is characterized by the dominance of *Bacteroides*, the lack of butyric acid-producing bacteria, and the decrease of bacterial and functional diversity. A study in which colonic bacteria released large amounts of acetic acid or butyrate by feeding NOD mice with specific foods found that the key characteristics of the disease were negatively correlated with the concentrations of butyrate and acetate in blood and feces[91]. The mechanism is believed to be that the acetate diet reduces the frequency of autoimmune T cells in lymphoid tissues, while butyrate diet increases the number and function of regulatory T cells[91]. Human studies have also shown that SCFAs are involved in the prevention mechanism of early-onset human T1D. A recent prospective study demonstrated the protective effect of SCFAs on early-onset human T1D. This study analyzed 10913 metagenomes from 783 stool samples, and increased several bacterial pathways that promote SCFAs biosynthesis was found in healthy controls[92].

However, unlike T2D, transfer of the whole microbiota may not reduce the incidence of T1D. Recently, a study investigated the incidence of T1D in two NOD groups with different gut microbiota. Afterwards, 16S rRNA gene sequencing was used to analyze the gut microbiota with high or low incidence of T1D in the two groups of NOD mice, and the high incidence population was colonized with the microflora of the low incidence population. The results showed that the gut microbiota changed but the incidence of diabetes did not[88]. In another study, germ-free mice received fecal microflora from children with loss of β-cells, the result of which indicated that loss of β-cells after human T1D onset cannot be converted in germ-free NOD mice by FMT[93]. However, it is interesting that single symbiotic bacteria, such as *A. muciniphila*, can be used as probiotics to reduce the incidence of diabetes[88]. LPS also participates in the regulation of autoimmunity, most of which are *Escherichia coli* LPS involved in suppressing innate immune signals, but *Bacteroides dorei* LPS does not show significant improvement in T1D incidence[94]. In a recent study, intraperitoneal injection of *Escherichia coli* LPS in T1D mice showed a decrease in the incidence of T1D and an improved autoimmune response[94], while another study of NOD mice that received oral injection of *Escherichia coli* LPS also demonstrated an improvement in local immunity[95]. The concept that the pathogenesis of T1D is affected by gut microbiota has been well established in mouse models, but human studies on the microbiome in T1D are still few and far between to provide convincing evidence.

Gut microbial colonization in fetuses and infants can lead to dynamic changes in diversity, which may further affect disease susceptibility. A study of 33 infants with T1D genetic predisposition observed a significant decrease in alpha diversity among T1D progenitors, along with peaks in inflammatory organisms, gene function, serum and fecal metabolites, and this diversity difference occurred after serum conversion and was determined to be specific to T1D[96].

The pre-clinical T1D patients' intestinal microflora is characterized by a dominant Bacteroides, with low stability and diversity of intestinal microflora. Studies have shown that these changes were found after the body produced auto-antibodies, which could indicate the role of gut microbiota in the autoimmune process, while the triggering mechanism of T1D disease was not determined[97]. There is growing evidence that islet autoimmunity is the first stage of T1D. Islet autoimmunity refers to the continuous existence of islet antigen autoantibodies, which usually begin in early childhood[98]. The role of gut microbiota in activating T1D is still a very vague concept, current studies have few observations or evidence to support the explanation that gut microbiota activates T1D, and most studies focus on the involvement of gut microbiota in the β-cell autoimmunity process. The causal relationship between intestinal microflora and T1D is still unclear, because most studies are only observational studies, and lack specific mechanical and intervention.

# ORAL MICROBIOTA: ANOTHER FACTOR OF GUT MICROBIOME AND DIABETES

As the starting point of the digestive tract, the importance of oral microbiota and its association with the intestinal microbiota are received increasing attention. The oral cavity serves as an endogenous reservoir for gut microbial strains, and oral-fecal transmission is an important process that shapes the gastrointestinal microbiome in both health and disease[99]. Oral bacteria can translocate to the gut and lead to changes in its microbiota and possibly immune defense. It has been recognized that oral microorganisms may cause diseases mainly by a synergistic or cooperative way, and oral diseases (*e.g.*, caries, periodontal disease) and T2D appear to be mutually correlated[100]. Studies have reported significant differences in oral microbiota between patients with T2D and non-diabetic patients. Oral microbial biomarkers have been identified for T2D screening, diagnosis and prognosis[101-103]. Recently, researchers provided a possible mechanism for the improved understanding of how diabetes increases the risk and severity of tooth loss. Diabetes may cause changes in oral bacterial composition, and the oral microbiota of diabetic mice was found to be more pathogenic in studies transplanting to germ-free mice[104]. These studies suggested that oral microbiota is an important factor in the development of diabetes, and on the other hand, oral microbiota is also an important avenue for diabetes to cause other oral or systemic complications. This new area of investigation may represent another pathway for the oral-gut axis to potentially cause an increase in diabetic disease and deserves more in-depth research moving forward.

# CONCLUSION

The current research into gut microbiome in the field of diabetes has gradually moved step by step from the initial correlation studies, which proved a strong association, to exploring the causality and potential mechanisms (Figure 1). It is very clear that as science looks to the future this will be a very promising frontier. It can be foreseen that the gut microbiota will be used not only as a biomarker for diabetes, but also as a target for potential therapeutic treatments. Through the intervention of gut microflora, it will eventually be possible to achieve a more precise and personalized diagnosis as well as treatment of diabetes (Table 1). This is only going to be possible with a significant investment in extensive multicenter, longitudinal, interventional and double-blind randomized clinical trials. Additionally, these will yield an extensive knowledge base upon which data science and exploration can occur. The scientific research community must proceed with a sense of urgency, if these data are to be used to their fullest advantage, as many new discoveries are waiting just ahead.

# REFERENCES

1 **Saeedi P**, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2019; **157**: 107843 [PMID: 31518657 DOI: 10.1016/j.diabres.2019.107843]

2 **Gowd V**, Xie L, Zheng X, Chen W. Dietary fibers as emerging nutritional factors against diabetes: focus on the involvement of gut microbiota. *Crit Rev Biotechnol* 2019; **39**: 524-540 [PMID: 30810398 DOI: 10.1080/07388551.2019.1576025]

3 **Brunkwall L**, Orho-Melander M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities. *Diabetologia* 2017; **60**: 943-951 [PMID: 28434033 DOI: 10.1007/s00125-017-4278-3]

4 **Azad MAK**, Sarker M, Li T, Yin J. Probiotic Species in the Modulation of Gut Microbiota: An Overview. *Biomed Res Int* 2018; **2018**: 9478630 [PMID: 29854813 DOI: 10.1155/2018/9478630]

5 **Saad MJ**, Santos A, Prada PO. Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. *Physiology* (Bethesda) 2016; **31**: 283-293 [PMID: 27252163 DOI: 10.1152/physiol.00041.2015]

6 **Han JL**, Lin HL. Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective. *World J Gastroenterol* 2014; **20**: 17737-17745 [PMID: 25548472 DOI: 10.3748/wjg.v20.i47.17737]

7 **Cox LM**, Blaser MJ. Antibiotics in early life and obesity. *Nat Rev Endocrinol* 2015; **11**: 182-190 [PMID: 25488483 DOI: 10.1038/nrendo.2014.210]

8 **Singh RK**, Chang HW, Yan D, Lee KM, Ucmak D, Wong K, Abrouk M, Farahnik B, Nakamura M, Zhu TH, Bhutani T, Liao W. Influence of diet on the gut microbiome and implications for human health. *J Transl Med* 2017; **15**: 73 [PMID: 28388917 DOI: 10.1186/s12967-017-1175-y]

9 **Makki K**, Deehan EC, Walter J, Bäckhed F. The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease. *Cell Host Microbe* 2018; **23**: 705-715 [PMID: 29902436 DOI: 10.1016/j.chom.2018.05.012]

10 **Vaiserman AM**, Koliada AK, Marotta F. Gut microbiota: A player in aging and a target for anti-aging intervention. *Ageing Res Rev* 2017; **35**: 36-45 [PMID: 28109835 DOI: 10.1016/j.arr.2017.01.001]

11 **Heath RD**, Cockerell C, Mankoo R, Ibdah JA, Tahan V. Fecal microbiota transplantation and its potential therapeutic uses in gastrointestinal disorders. *North Clin Istanb* 2018; **5**: 79-88 [PMID: 29607440 DOI: 10.14744/nci.2017.10692]

12 **Sonnenburg JL**, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. *Nature* 2016; **535**: 56-64 [PMID: 27383980 DOI: 10.1038/nature18846]

13 **Martínez I**, Lattimer JM, Hubach KL, Case JA, Yang J, Weber CG, Louk JA, Rose DJ, Kyureghian G, Peterson DA, Haub MD, Walter J. Gut microbiome composition is linked to whole grain-induced immunological improvements. *ISME J* 2013; **7**: 269-280 [PMID: 23038174 DOI: 10.1038/ismej.2012.104]

14 **Tap J**, Furet JP, Bensaada M, Philippe C, Roth H, Rabot S, Lakhdari O, Lombard V, Henrissat B, Corthier G, Fontaine E, Doré J, Leclerc M. Gut microbiota richness promotes its stability upon increased dietary fibre intake in healthy adults. *Environ Microbiol* 2015; **17**: 4954-4964 [PMID: 26235304 DOI: 10.1111/1462-2920.13006]

15 **Gholizadeh P**, Mahallei M, Pormohammad A, Varshochi M, Ganbarov K, Zeinalzadeh E, Yousefi B, Bastami M, Tanomand A, Mahmood SS, Yousefi M, Asgharzadeh M, Kafil HS. Microbial balance in the intestinal microbiota and its association with diabetes, obesity and allergic disease. *Microb Pathog* 2019; **127**: 48-55 [PMID: 30503960 DOI: 10.1016/j.micpath.2018.11.031]

16 **Davila AM**, Blachier F, Gotteland M, Andriamihaja M, Benetti PH, Sanz Y, Tomé D. Intestinal luminal nitrogen metabolism: role of the gut microbiota and consequences for the host. *Pharmacol Res* 2013; **68**: 95-107 [PMID: 23183532 DOI: 10.1016/j.phrs.2012.11.005]

17 **Neis EP**, Dejong CH, Rensen SS. The role of microbial amino acid metabolism in host metabolism. *Nutrients* 2015; **7**: 2930-2946 [PMID: 25894657 DOI: 10.3390/nu7042930]

18 **Fuller S**, Beck E, Salman H, Tapsell L. New Horizons for the Study of Dietary Fiber and Health: A Review. *Plant Foods Hum Nutr* 2016; **71**: 1-12 [PMID: 26847187 DOI: 10.1007/s11130-016-0529-6]

19 **Dahl WJ**, Stewart ML. Position of the Academy of Nutrition and Dietetics: Health Implications of Dietary Fiber. *J Acad Nutr Diet* 2015; **115**: 1861-1870 [PMID: 26514720 DOI: 10.1016/j.jand.2015.09.003]

20 **Kasubuchi M**, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. *Nutrients* 2015; **7**: 2839-2849 [PMID: 25875123 DOI: 10.3390/nu7042839]

21 **Zeevi D**, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalová L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. *Cell* 2015; **163**: 1079-1094 [PMID: 26590418 DOI: 10.1016/j.cell.2015.11.001]

22 **Wang DD**, Hu FB. Precision nutrition for prevention and management of type 2 diabetes. *Lancet Diabetes Endocrinol* 2018; **6**: 416-426 [PMID: 29433995 DOI: 10.1016/S2213-8587(18)30037-8]

23 **Cani PD**, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. *Curr Pharm Des* 2009; **15**: 1546-1558 [PMID: 19442172 DOI: 10.2174/138161209788168164]

24 **Yoo JY**, Kim SS. Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders. *Nutrients* 2016; **8**: 173 [PMID: 26999199 DOI: 10.3390/nu8030173]

25 **Gavin PG**, Hamilton-Williams EE. The gut microbiota in type 1 diabetes: friend or foe? *Curr Opin Endocrinol Diabetes Obes* 2019; **26**: 207-212 [PMID: 31145129 DOI: 10.1097/MED.0000000000000483]

26 **Stewart CJ**, Ajami NJ, O'Brien JL, Hutchinson DS, Smith DP, Wong MC, Ross MC, Lloyd RE, Doddapaneni H, Metcalf GA, Muzny D, Gibbs RA, Vatanen T, Huttenhower C, Xavier RJ, Rewers M, Hagopian W, Toppari J, Ziegler AG, She JX, Akolkar B, Lernmark A, Hyoty H, Vehik K, Krischer JP, Petrosino JF. Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature* 2018; **562**: 583-588 [PMID: 30356187 DOI: 10.1038/s41586-018-0617-x]

27 **Allin KH**, Tremaroli V, Caesar R, Jensen BAH, Damgaard MTF, Bahl MI, Licht TR, Hansen TH, Nielsen T, Dantoft TM, Linneberg A, Jørgensen T, Vestergaard H, Kristiansen K, Franks PW; IMI-DIRECT consortium, Hansen T, Bäckhed F, Pedersen O. Aberrant intestinal microbiota in individuals with prediabetes. *Diabetologia* 2018; **61**: 810-820 [PMID: 29379988 DOI: 10.1007/s00125-018-4550-1]

28 **Nguyen TL**, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? *Dis Model Mech* 2015; **8**: 1-16 [PMID: 25561744 DOI: 10.1242/dmm.017400]

29 **Bäckhed F**, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci U S A*2004; **101**: 15718-15723 [PMID: 15505215 DOI: 10.1073/pnas.0407076101]

30 **Turnbaugh PJ**, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006; **444**: 1027-1031 [PMID: 17183312 DOI: 10.1038/nature05414]

31 **Tremaroli V**, Karlsson F, Werling M, Ståhlman M, Kovatcheva-Datchary P, Olbers T, Fändriks L, le Roux CW, Nielsen J, Bäckhed F. Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. *Cell Metab* 2015; **22**: 228-238 [PMID: 26244932 DOI: 10.1016/j.cmet.2015.07.009]

32 **Zhao L**. The gut microbiota and obesity: from correlation to causality. *Nat Rev Microbiol* 2013; **11**: 639-647 [PMID: 23912213 DOI: 10.1038/nrmicro3089]

33 **Meijnikman AS**, Gerdes VE, Nieuwdorp M, Herrema H. Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans. *Endocr Rev* 2018; **39**: 133-153 [PMID: 29309555 DOI: 10.1210/er.2017-00192]

34 **Smits LP**, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. *Gastroenterology* 2013; **145**: 946-953 [PMID: 24018052 DOI: 10.1053/j.gastro.2013.08.058]

35 **Hartstra AV**, Bouter KE, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. *Diabetes Care* 2015; **38**: 159-165 [PMID: 25538312 DOI: 10.2337/dc14-0769]

36 **Forslund K**, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H, Hercog R, Costea PI, Kultima JR, Li J, Jørgensen T, Levenez F, Dore J; MetaHIT consortium, Nielsen HB, Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature* 2015; **528**: 262-266 [PMID: 26633628 DOI: 10.1038/nature15766]

37 **McCreight LJ**, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. *Diabetologia* 2016; **59**: 426-435 [PMID: 26780750 DOI: 10.1007/s00125-015-3844-9]

38 **Vallianou NG**, Stratigou T, Tsagarakis S. Metformin and gut microbiota: their interactions and their impact on diabetes. *Hormones (Athens)* 2019; **18**: 141-144 [PMID: 30719628 DOI: 10.1007/s42000-019-00093-w]

39 **Wu H**, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM, Bäckhed F. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. *Nat Med* 2017; **23**: 850-858 [PMID: 28530702 DOI: 10.1038/nm.4345]

40 **Shin NR**, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut* 2014; **63**: 727-735 [PMID: 23804561 DOI: 10.1136/gutjnl-2012-303839]

41 **de la Cuesta-Zuluaga J**, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía EP, Carmona JA, Abad JM, Escobar JS. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. *Diabetes Care* 2017; **40**: 54-62 [PMID: 27999002 DOI: 10.2337/dc16-1324]

42 **Zhang F**, Wang M, Yang J, Xu Q, Liang C, Chen B, Zhang J, Yang Y, Wang H, Shang Y, Wang Y, Mu X, Zhu D, Zhang C, Yao M, Zhang L. Response of gut microbiota in type 2 diabetes to hypoglycemic agents. *Endocrine* 2019; **66**: 485-493 [PMID: 31410749 DOI: 10.1007/s12020-019-02041-5]

43 **Kim YA**, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin sensitivity. *Nutr Res Rev* 2018; **31**: 35-51 [PMID: 29037268 DOI: 10.1017/S095442241700018X]

44 **George Kerry R**, Patra JK, Gouda S, Park Y, Shin HS, Das G. Benefaction of probiotics for human health: A review. *J Food Drug Anal* 2018; **26**: 927-939 [PMID: 29976412 DOI: 10.1016/j.jfda.2018.01.002]

45 **Wen L**, Duffy A. Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. *J Nutr* 2017; **147**: 1468S-1475S [PMID: 28615382 DOI: 10.3945/jn.116.240754]

46 **Simon MC**, Strassburger K, Nowotny B, Kolb H, Nowotny P, Burkart V, Zivehe F, Hwang JH, Stehle P, Pacini G, Hartmann B, Holst JJ, MacKenzie C, Bindels LB, Martinez I, Walter J, Henrich B, Schloot NC, Roden M. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. *Diabetes Care* 2015; **38**: 1827-1834 [PMID: 26084343 DOI: 10.2337/dc14-2690]

47 **Zhang X**, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, Chen Y, Ji L. Human gut microbiota changes reveal the progression of glucose intolerance. *PLoS One* 2013; **8**: e71108 [PMID: 24013136 DOI: 10.1371/journal.pone.0071108]

48 **Chelakkot C**, Choi Y, Kim DK, Park HT, Ghim J, Kwon Y, Jeon J, Kim MS, Jee YK, Gho YS, Park HS, Kim YK, Ryu SH. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. *Exp Mol Med* 2018; **50**: e450 [PMID: 29472701 DOI: 10.1038/emm.2017.282]

49 **Schneeberger M**, Everard A, Gómez-Valadés AG, Matamoros S, Ramírez S, Delzenne NM, Gomis R, Claret M, Cani PD. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. *Sci Rep* 2015; **5**: 16643 [PMID: 26563823 DOI: 10.1038/srep16643]

50 **Anhê FF**, Roy D, Pilon G, Dudonné S, Matamoros S, Varin TV, Garofalo C, Moine Q, Desjardins Y, Levy E, Marette A. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. *Gut* 2015; **64**: 872-883 [PMID: 25080446 DOI: 10.1136/gutjnl-2014-307142]

51 **Dao MC**, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L; MICRO-Obes Consortium, Dumas ME, Rizkalla SW, Doré J, Cani PD, Clément K. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut* 2016; **65**: 426-436 [PMID: 26100928 DOI: 10.1136/gutjnl-2014-308778]

52 **Plovier H**, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med* 2017; **23**: 107-113 [PMID: 27892954 DOI: 10.1038/nm.4236]

53 **Depommier C**, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, Falony G, Raes J, Maiter D, Delzenne NM, de Barsy M, Loumaye A, Hermans MP, Thissen JP, de Vos WM, Cani PD. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. *Nat Med* 2019; **25**: 1096-1103 [PMID: 31263284 DOI: 10.1038/s41591-019-0495-2]

54 **Badehnoosh B**, Karamali M, Zarrati M, Jamilian M, Bahmani F, Tajabadi-Ebrahimi M, Jafari P, Rahmani E, Asemi Z. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. *J Matern Fetal Neonatal Med* 2018; **31**: 1128-1136 [PMID: 28326881 DOI: 10.1080/14767058.2017.1310193]

55 **Callaway LK**, McIntyre HD, Barrett HL, Foxcroft K, Tremellen A, Lingwood BE, Tobin JM, Wilkinson S, Kothari A, Morrison M, O'Rourke P, Pelecanos A, Dekker Nitert M. Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-Blind Randomized Controlled Trial. *Diabetes Care* 2019; **42**: 364-371 [PMID: 30659070 DOI: 10.2337/dc18-2248]

56 **Gurung M**, Li Z, You H, Rodrigues R, Jump DB, Morgun A, Shulzhenko N. Role of gut microbiota in type 2 diabetes pathophysiology. *EBioMedicine* 2020; **51**: 102590 [PMID: 31901868 DOI: 10.1016/j.ebiom.2019.11.051]

57 **O'Hara AM**, Shanahan F. The gut flora as a forgotten organ. *EMBO Rep* 2006; **7**: 688-693 [PMID: 16819463 DOI: 10.1038/sj.embor.7400731]

58 **Tang WH**, Kitai T, Hazen SL. Gut Microbiota in Cardiovascular Health and Disease. *Circ Res* 2017; **120**: 1183-1196 [PMID: 28360349 DOI: 10.1161/CIRCRESAHA.117.309715]

59 **Blaut M**, Klaus S. Intestinal microbiota and obesity. *Handb Exp Pharmacol* 2012; : 251-273 [PMID: 22249818 DOI: 10.1007/978-3-642-24716-3\_11]

60 **Boutagy NE**, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxemia with obesity: Is it real and is it relevant? *Biochimie* 2016; **124**: 11-20 [PMID: 26133659 DOI: 10.1016/j.biochi.2015.06.020]

61 **Rogero MM**, Calder PC. Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids. *Nutrients* 2018; **10**: [PMID: 29601492 DOI: 10.3390/nu10040432]

62 **Odenwald MA**, Turner JR. The intestinal epithelial barrier: a therapeutic target? *Nat Rev Gastroenterol Hepatol* 2017; **14**: 9-21 [PMID: 27848962 DOI: 10.1038/nrgastro.2016.169]

63 **Bron PA**, Kleerebezem M, Brummer RJ, Cani PD, Mercenier A, MacDonald TT, Garcia-Ródenas CL, Wells JM. Can probiotics modulate human disease by impacting intestinal barrier function? *Br J Nutr* 2017; **117**: 93-107 [PMID: 28102115 DOI: 10.1017/S0007114516004037]

64 **Woting A**, Blaut M. The Intestinal Microbiota in Metabolic Disease. *Nutrients* 2016; **8**: 202 [PMID: 27058556 DOI: 10.3390/nu8040202]

65 **Delzenne NM**, Cani PD. Gut microbiota and the pathogenesis of insulin resistance. *Curr Diab Rep* 2011; **11**: 154-159 [PMID: 21431853 DOI: 10.1007/s11892-011-0191-1]

66 **Peng L**, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. *J Nutr* 2009; **139**: 1619-1625 [PMID: 19625695 DOI: 10.3945/jn.109.104638]

67 **Suzuki T**, Yoshida S, Hara H. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. *Br J Nutr* 2008; **100**: 297-305 [PMID: 18346306 DOI: 10.1017/S0007114508888733]

68 **Zhao L**, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H, Xue X, Lu C, Ma J, Yu L, Xu C, Ren Z, Xu Y, Xu S, Shen H, Zhu X, Shi Y, Shen Q, Dong W, Liu R, Ling Y, Zeng Y, Wang X, Zhang Q, Wang J, Wang L, Wu Y, Zeng B, Wei H, Zhang M, Peng Y, Zhang C. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science* 2018; **359**: 1151-1156 [PMID: 29590046 DOI: 10.1126/science.aao5774]

69 **Goswami C**, Iwasaki Y, Yada T. Short-chain fatty acids suppress food intake by activating vagal afferent neurons. *J Nutr Biochem* 2018; **57**: 130-135 [PMID: 29702431 DOI: 10.1016/j.jnutbio.2018.03.009]

70 **Sanna S**, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, Mujagic Z, Masclee AAM, Jonkers DMAE, Oosting M, Joosten LAB, Netea MG, Franke L, Zhernakova A, Fu J, Wijmenga C, McCarthy MI. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. *Nat Genet* 2019; **51**: 600-605 [PMID: 30778224 DOI: 10.1038/s41588-019-0350-x]

71 **Vrieze A**, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* 2012; **143**: 913-6.e7 [PMID: 22728514 DOI: 10.1053/j.gastro.2012.06.031]

72 **Jumpertz R**, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, Krakoff J. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. *Am J Clin Nutr* 2011; **94**: 58-65 [PMID: 21543530 DOI: 10.3945/ajcn.110.010132]

73 **Tamanai-Shacoori Z**, Smida I, Bousarghin L, Loreal O, Meuric V, Fong SB, Bonnaure-Mallet M, Jolivet-Gougeon A. Roseburia spp.: a marker of health? *Future Microbiol* 2017; **12**: 157-170 [PMID: 28139139 DOI: 10.2217/fmb-2016-0130]

74 **Fiorucci S**, Distrutti E. Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders. *Trends Mol Med* 2015; **21**: 702-714 [PMID: 26481828 DOI: 10.1016/j.molmed.2015.09.001]

75 **Islam KB**, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. *Gastroenterology* 2011; **141**: 1773-1781 [PMID: 21839040 DOI: 10.1053/j.gastro.2011.07.046]

76 **Pathak P**, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, Patterson AD, Gonzalez FJ, Chiang JYL. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. *Hepatology* 2018; **68**: 1574-1588 [PMID: 29486523 DOI: 10.1002/hep.29857]

77 **Prawitt J**, Abdelkarim M, Stroeve JH, Popescu I, Duez H, Velagapudi VR, Dumont J, Bouchaert E, van Dijk TH, Lucas A, Dorchies E, Daoudi M, Lestavel S, Gonzalez FJ, Oresic M, Cariou B, Kuipers F, Caron S, Staels B. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. *Diabetes* 2011; **60**: 1861-1871 [PMID: 21593203 DOI: 10.2337/db11-0030]

78 **Massafra V**, van Mil SWC. Farnesoid X receptor: A "homeostat" for hepatic nutrient metabolism. *Biochim Biophys Acta Mol Basis Dis* 2018; **1864**: 45-59 [PMID: 28986309 DOI: 10.1016/j.bbadis.2017.10.003]

79 **Thomas C**, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. *Cell Metab* 2009; **10**: 167-177 [PMID: 19723493 DOI: 10.1016/j.cmet.2009.08.001]

80 **Wang TJ**, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. *Nat Med* 2011; **17**: 448-453 [PMID: 21423183 DOI: 10.1038/nm.2307]

81 **Giesbertz P**, Daniel H. Branched-chain amino acids as biomarkers in diabetes. *Curr Opin Clin Nutr Metab Care* 2016; **19**: 48-54 [PMID: 26485337 DOI: 10.1097/MCO.0000000000000235]

82 **Niewczas MA**, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, Smiles A, Huang X, Walker W, Byun J, Karoly ED, Kensicki EM, Berry GT, Bonventre JV, Pennathur S, Meyer TW, Krolewski AS. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. *Kidney Int* 2014; **85**: 1214-1224 [PMID: 24429397 DOI: 10.1038/ki.2013.497]

83 **Huang M**, Liang Q, Li P, Xia J, Wang Y, Hu P, Jiang Z, He Y, Pang L, Han L, Wang Y, Luo G. Biomarkers for early diagnosis of type 2 diabetic nephropathy: a study based on an integrated biomarker system. *Mol Biosyst* 2013; **9**: 2134-2141 [PMID: 23719966 DOI: 10.1039/c3mb25543c]

84 **Newgard CB**, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab* 2009; **9**: 311-326 [PMID: 19356713 DOI: 10.1016/j.cmet.2009.02.002]

85 **Asghari G**, Farhadnejad H, Teymoori F, Mirmiran P, Tohidi M, Azizi F. High dietary intake of branched-chain amino acids is associated with an increased risk of insulin resistance in adults. *J Diabetes* 2018; **10**: 357-364 [PMID: 29281182 DOI: 10.1111/1753-0407.12639]

86 **Pedersen HK**, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, Forslund K, Hildebrand F, Prifti E, Falony G, Le Chatelier E, Levenez F, Doré J, Mattila I, Plichta DR, Pöhö P, Hellgren LI, Arumugam M, Sunagawa S, Vieira-Silva S, Jørgensen T, Holm JB, Trošt K; MetaHIT Consortium, Kristiansen K, Brix S, Raes J, Wang J, Hansen T, Bork P, Brunak S, Oresic M, Ehrlich SD, Pedersen O. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature* 2016; **535**: 376-381 [PMID: 27409811 DOI: 10.1038/nature18646]

87 **Kawaguchi T**, Izumi N, Charlton MR, Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. *Hepatology* 2011; **54**: 1063-1070 [PMID: 21563202 DOI: 10.1002/hep.24412]

88 **Hänninen A**, Toivonen R, Pöysti S, Belzer C, Plovier H, Ouwerkerk JP, Emani R, Cani PD, De Vos WM. *Akkermansia muciniphila* induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. *Gut* 2018; **67**: 1445-1453 [PMID: 29269438 DOI: 10.1136/gutjnl-2017-314508]

89 **Wen L**, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, Gordon JI, Chervonsky AV. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. *Nature* 2008; **455**: 1109-1113 [PMID: 18806780 DOI: 10.1038/nature07336]

90 **Peng J**, Narasimhan S, Marchesi JR, Benson A, Wong FS, Wen L. Long term effect of gut microbiota transfer on diabetes development. *J Autoimmun* 2014; **53**: 85-94 [PMID: 24767831 DOI: 10.1016/j.jaut.2014.03.005]

91 **Mariño E**, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J, McKenzie C, Kranich J, Oliveira AC, Rossello FJ, Krishnamurthy B, Nefzger CM, Macia L, Thorburn A, Baxter AG, Morahan G, Wong LH, Polo JM, Moore RJ, Lockett TJ, Clarke JM, Topping DL, Harrison LC, Mackay CR. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. *Nat Immunol* 2017; **18**: 552-562 [PMID: 28346408 DOI: 10.1038/ni.3713]

92 **Vatanen T**, Franzosa EA, Schwager R, Tripathi S, Arthur TD, Vehik K, Lernmark Å, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Stewart CJ, Ajami NJ, Petrosino JF, Gevers D, Lähdesmäki H, Vlamakis H, Huttenhower C, Xavier RJ. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature* 2018; **562**: 589-594 [PMID: 30356183 DOI: 10.1038/s41586-018-0620-2]

93 **Neuman V**, Cinek O, Funda DP, Hudcovic T, Golias J, Kramna L, Petruzelkova L, Pruhova S, Sumnik Z. Human gut microbiota transferred to germ-free NOD mice modulate the progression towards type 1 diabetes regardless of the pace of beta cell function loss in the donor. *Diabetologia* 2019; **62**: 1291-1296 [PMID: 31025045 DOI: 10.1007/s00125-019-4869-2]

94 **Vatanen T**, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, Vlamakis H, Arthur TD, Hämäläinen AM, Peet A, Tillmann V, Uibo R, Mokurov S, Dorshakova N, Ilonen J, Virtanen SM, Szabo SJ, Porter JA, Lähdesmäki H, Huttenhower C, Gevers D, Cullen TW, Knip M; DIABIMMUNE Study Group, Xavier RJ. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. *Cell* 2016; **165**: 842-853 [PMID: 27133167 DOI: 10.1016/j.cell.2016.04.007]

95 **Kihl P**, Krych L, Deng L, Kildemoes AO, Laigaard A, Hansen LH, Hansen CHF, Buschard K, Nielsen DS, Hansen AK. Oral LPS Dosing Induces Local Immunological Changes in the Pancreatic Lymph Nodes in Mice. *J Diabetes Res* 2019; **2019**: 1649279 [PMID: 30956991 DOI: 10.1155/2019/1649279]

96 **Kostic AD**, Gevers D, Siljander H, Vatanen T, Hyötyläinen T, Hämäläinen AM, Peet A, Tillmann V, Pöhö P, Mattila I, Lähdesmäki H, Franzosa EA, Vaarala O, de Goffau M, Harmsen H, Ilonen J, Virtanen SM, Clish CB, Orešič M, Huttenhower C, Knip M; DIABIMMUNE Study Group, Xavier RJ. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. *Cell Host Microbe* 2015; **17**: 260-273 [PMID: 25662751 DOI: 10.1016/j.chom.2015.01.001]

97 **Knip M**, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. *Nat Rev Endocrinol* 2016; **12**: 154-167 [PMID: 26729037 DOI: 10.1038/nrendo.2015.218]

98 **Rewers M**, Ludvigsson J. Environmental risk factors for type 1 diabetes. *Lancet* 2016; **387**: 2340-2348 [PMID: 27302273 DOI: 10.1016/S0140-6736(16)30507-4]

99 **Schmidt TS**, Hayward MR, Coelho LP, Li SS, Costea PI, Voigt AY, Wirbel J, Maistrenko OM, Alves RJ, Bergsten E, de Beaufort C, Sobhani I, Heintz-Buschart A, Sunagawa S, Zeller G, Wilmes P, Bork P. Extensive transmission of microbes along the gastrointestinal tract. *Elife* 2019; **8**: [PMID: 30747106 DOI: 10.7554/eLife.42693]

100 **He J**, Li Y, Cao Y, Xue J, Zhou X. The oral microbiome diversity and its relation to human diseases. *Folia Microbiol (Praha)* 2015; **60**: 69-80 [PMID: 25147055 DOI: 10.1007/s12223-014-0342-2]

101 **Chen B**, Wang Z, Wang J, Su X, Yang J, Zhang Q, Zhang L. The oral microbiome profile and biomarker in Chinese type 2 diabetes mellitus patients. *Endocrine* 2020; : [PMID: 32246318 DOI: 10.1007/s12020-020-02269-6]

102 **Long J**, Cai Q, Steinwandel M, Hargreaves MK, Bordenstein SR, Blot WJ, Zheng W, Shu XO. Association of oral microbiome with type 2 diabetes risk. *J Periodontal Res* 2017; **52**: 636-643 [PMID: 28177125 DOI: 10.1111/jre.12432]

103 **Matsha TE**, Prince Y, Davids S, Chikte U, Erasmus RT, Kengne AP, Davison GM. Oral Microbiome Signatures in Diabetes Mellitus and Periodontal Disease. *J Dent Res* 2020; **99**: 658-665 [PMID: 32298191 DOI: 10.1177/0022034520913818]

104 **Xiao E**, Mattos M, Vieira GHA, Chen S, Corrêa JD, Wu Y, Albiero ML, Bittinger K, Graves DT. Diabetes Enhances IL-17 Expression and Alters the Oral Microbiome to Increase Its Pathogenicity. *Cell Host Microbe* 2017; **22**: 120-128.e124 [PMID: 28704648 DOI: 10.1016/j.chom.2017.06.014]

105 **Hurst NR**, Kendig DM, Murthy KS, Grider JR. The short chain fatty acids, butyrate and propionate, have differential effects on the motility of the guinea pig colon. *Neurogastroenterol Motil* 2014; **26**: 1586-1596 [PMID: 25223619 DOI: 10.1111/nmo.12425]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Peer-review started:** February 29, 2020

**First decision:** April 7, 2020

**Article in press:** June 10, 2020

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Das U, Liu J **S-Editor:** Ma RY **L-Editor:** Webster JR **E-Editor:** Wang LL

**Figure Legends**



Gut microbiota(Microbial components and metabolic products)

Medication

T-cell

Genetics

Diet

Intervention studies

FMTMetformin Probiotics and prebiotics

SCFAs

FFAR2FFAR3

TGR5

L cell

PYY

GLP-1

Insulin sensitivity

FGF15/19

FXR

Secondarybile acids

Bile acids

Liver

Pancreas

Insulin resistance

Low-grade inflammation

TLR4

LPS

**Figure 1** **The main mechanism of gut microbiota affecting insulin resistance and diabetes.** Gut microbes are influenced by diet, genetics and medication, and common types of interventions in humans include fecal microbiota transplantation, metformin and probiotics. Lipopolysaccharide (LPS), short-chain fatty acids (SCFAs) and bile acids are major regulators of diabetes. LPS binds to the Toll-like receptor 4 to induce low-grade inflammation and insulin resistance. Bile acids are synthesized by the liver and transformed into secondary bile acids through the metabolism of gut microbiota. Secondary bile acids activate Farnesoid X receptor to induce increased secretion of fibroblast growth factor 15/19. Secondary bile acids activate Takeda G protein-coupled receptor to stimulate intestinal L cells to secrete glucagon-like peptide-1 (GLP-1). SCFAs activate L cells to promote the release of GLP-1 and peptide YY to increase insulin sensitivity. SCFAs also have a regulatory effect on T cells. LPS: Lipopolysaccharide; TLR4: Toll-like receptor 4; FXR: Farnesoid X receptor; FGF15/19: Fibroblast growth factor 15/19; TGR5: Takeda G protein-coupled receptor 5; PYY: Peptide YY; GLP-1: Glucagon-like peptide-1; SCFAs: Short-chain fatty acids; FFAR 2: Free fatty acid receptor 2; FFAR 3: Free fatty acid receptor 3; FMT: Fecal microbiota transplantation.

**Table 1 A summary of products of gut microbiota and their mechanism of action**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Gut microbiota products** | | **Source** | **Mechanism** | **Function** | | **Ref.** |
| LPS |  | The cell wall of Gram-negative bacteria | Activates the receptor TLR4 | Increase the occurrence of inflammatory response | | [59,60] |
| SCFAs | Acetate | Carbohydrate fermentation | Activates the receptor FFAR2 | Reduce the frequency of autoimmune T cells in lymphoid tissues | FFAR2 and FFAR3 stimulate the release of GLP-1 and PYY, which improve insulin secretion. | [15,91,105] |
| Propionate | Activates the receptor FFAR2 and FFAR3 | Promote intestinal gluconeogenesis |
| Butyrate | Activates the receptor FFAR3 | Increase the number and function of regulatory T cells |
| Bile acids |  | The microbiota from host cholesterol | Bind to the receptor TGR5 and FXR | Improve and insulin sensitivity | | [74,76] |
| BCAA |  | *Prevotella copri* and *Bacteroides vulgatus* | Activate PI3K and increase the oxidation of free fatty acids | Increase the risk of insulin resistance | | [86,87] |

LPS: Lipopolysaccharide; TLR4: Toll-like receptor 4; SCFAs: Short-chain fatty acids; FFAR 2: Free fatty acid receptor 2; FFAR 3: Free fatty acid receptor 3; GLP-1: Glucagon-like peptide-1; PYY: Peptide YY; TGR5: Takeda G protein-coupled receptor 5; FXR: Farnesoid X receptor; BCAA: Branched-Chain Amino Acids; PI3K: Phosphatidylinositol 3-kinase.